Lyell Immunopharma Future Growth
Future criteria checks 2/6
Lyell Immunopharma's earnings are forecast to decline at 11.8% per annum while its annual revenue is expected to grow at 53.3% per year. EPS is expected to decline by 0.2% per annum. Return on equity is forecast to be -74.3% in 3 years.
Key information
-11.8%
Earnings growth rate
-0.2%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 53.3% |
| Future return on equity | -74.3% |
| Analyst coverage | Low |
| Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -343 | -221 | -218 | 1 |
| 12/31/2025 | 3 | -259 | -183 | -180 | 4 |
| 12/31/2024 | 2 | -225 | -161 | -158 | 5 |
| 12/31/2023 | 0 | -235 | -166 | -164 | N/A |
| 9/30/2023 | 49 | -190 | -171 | -163 | N/A |
| 6/30/2023 | 48 | -209 | -173 | -163 | N/A |
| 3/31/2023 | 84 | -182 | -184 | -168 | N/A |
| 12/31/2022 | 85 | -183 | -194 | -170 | N/A |
| 9/30/2022 | 39 | -258 | -192 | -163 | N/A |
| 6/30/2022 | 42 | -237 | -190 | -151 | N/A |
| 3/31/2022 | 9 | -263 | -197 | -141 | N/A |
| 12/31/2021 | 11 | -250 | -192 | -126 | N/A |
| 9/30/2021 | 10 | -205 | -200 | -120 | N/A |
| 6/30/2021 | 8 | -192 | -197 | -116 | N/A |
| 3/31/2021 | 9 | -230 | -235 | -171 | N/A |
| 12/31/2020 | 8 | -208 | -212 | -161 | N/A |
| 12/31/2019 | 1 | -131 | 23 | 39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LYEL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LYEL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LYEL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LYEL's revenue (53.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: LYEL's revenue (53.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LYEL is forecast to be unprofitable in 3 years.